Asset profile
OD-07656
Small molecule
Evidence outlook · lead readout
NCT06206811 · Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis, Spondyloarthritis
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06206811: All participants across every part of this study received OD-07656 itself, with no placebo or control group and only single-blinding of the participant, so there is no comparison group to assess safety findings against; results have not yet been posted.
Also in development:Crohn's Disease · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.